Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1443 • ACR Convergence 2021
Long-term Effectiveness of Ultra-Low Doses of Rituximab in Rheumatoid Arthritis
Nathan den Broeder¹, Lise Verhoef², Yael De Man³, Marc Kok⁴, Rogier Thurlings⁵, Wilfred van der Weele⁶, Bart van den Bemt⁷, Frank van den Hoogen⁸, Aatke van der Maas⁹ and Alfons den Broeder¹⁰, ¹Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Ziekenhuisgroep Twente (Hospital Group Twente), Borne, Netherlands, ⁴Maasstad Hospital, Rotterdam, Netherlands, ⁵Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Reade, Amsterdam, Netherlands, ⁷Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁸Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁹St Maartenskliniek, Nijmegen, Gelderland, Netherlands, ¹⁰Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: The optimal rituximab (RTX) dose for the treatment of rheumatoid arthritis remains unclear. RTX treatment of 1000mg per 6 months and 2000mg per 6…
Abstract Number: 1603 • ACR Convergence 2021
COVID-19 Vaccination Experience in Patients with Rheumatoid Arthritis Treated at the Cleveland VA Medical Center
Sarah Abi Doumeth¹, Laura Silversteyn², Donald Anthony² and Maya Mattar³, ¹University hospitals Cleveland medical center, Cleveland, OH, ²Louis Stokes Cleveland VA Medical Center, Cleveland, OH, ³Louis Stokes VA Medical Center, Mayfield Heights, OH
Background/Purpose: Following the introduction of the COVID-19 vaccines, there has been uncertainty as to whether receiving the COVID-19 vaccine would result in overactivation of the…
Abstract Number: 1661 • ACR Convergence 2021
Sex-Stratified Patterns of Multimorbidity at RA Onset and Associated Longitudinal Impacts on Disability Over the First Year Follow Up: Results from the Canadian Early Arthritis Cohort (CATCH)
Orit Schieir¹, Susan Bartlett², Marie-France Valois², Louis Bessette³, Gilles Boire⁴, Glen Hazlewood⁵, Edward Keystone⁶, Janet Pope⁷, Carter Thorne⁸, Diane Tin⁸ and Vivian Bykerk⁹, ¹Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁷University of Western Ontario, London, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Chronic disease multimorbidity (MM) is prevalent in RA. As MM can vary in complexity and different combinations of chronic conditions may have different physical…
Abstract Number: 1677 • ACR Convergence 2021
Effects of Biological-DMARDs on the Serum Low-density Lipoprotein (LDL) / High-density Lipoprotein (HDL) – Cholesterol Ratio in Patients with Rheumatoid Arthritis
Yusuke Miwa¹ and Yuko Mitamura², ¹Division of Rheumatology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Shinagawa-ku, Japan
Background/Purpose: Rheumatoid arthritis (RA) and dyslipidemia are associated with inflammation. Although the low-density lipoprotein cholesterol (LDL-C) is normal range, the high-density lipoprotein cholesterol (HDL-C) is…
Abstract Number: 1693 • ACR Convergence 2021
Lower Adverse Event and Infection Rates During Tocilizumab Therapy Without Concomitant GC: An Analysis of the ICHIBAN Study
Christof Specker¹, Martin Aringer², Gerd Burmester³, Marvin A. Peters⁴, Michael W. Hofmann⁵, Herbert Kellner⁶, Frank Moosig⁷, Hans-Peter Tony⁸ and Gerhard Fliedner⁹, ¹Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Roche Pharma AG, Grenzach-Wyhlen, Germany, ⁵Chugai Pharma Germany GmbH, Frankfurt am Main, Germany, ⁶Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany, ⁷Rheumatology Center Schleswig-Holstein Middle, Neumünster, Germany, ⁸Universitätsklinikum Würzburg, Wuerzburg, Germany, ⁹Rheumatology Practice, Osnabrueck, Germany
Background/Purpose: To limit the risk of serious infections, guidelines recommend short term (< 3 months) or low-dose (≤10 mg/day) adjunct glucocorticoids (GCs) to control rheumatoid…
Abstract Number: 1710 • ACR Convergence 2021
Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial
Daniel Aletaha¹, Rene Westhovens², Tatsuya Atsumi³, YingMeei Tan⁴, Alena Pechonkina⁵, Qi Gong⁵, Vijay Rajendran⁶, Sander Strengholt⁷ and Gerd Burmester⁸, ¹Medical University Vienna, Vienna, Austria, ²University Hospitals KU Leuven, Maaseik, Belgium, ³Hokkaido University, Sapporo, Japan, ⁴Gilead Sciences, Inc, San Diego, CA, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos, BV, New York, NY, ⁸Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. In this…
Abstract Number: 1925 • ACR Convergence 2021
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Sahil Koppikar¹, Bindee Kuriya², Jacob Udell³, Bing Yu⁴, Anna Chu⁴, Laura Ferreira-Legere⁵, Douglas Lee³, Jessica Widdifield⁶ and Lihi Eder³, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴ICES, Toronto, ON, Canada, ⁵ICES, Toronto, Canada, ⁶Sunnybrook Research Institute; ICES; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…
Abstract Number: 0024 • ACR Convergence 2021
Heterogeneity of Inflammatory HLA-DR+ Synovial Fibroblasts in Rheumatoid Arthritis Is Driven by Responses to Leukocyte-Derived Cytokines
Melanie Smith¹, Alejandro Kochen¹, Vianne Gao², Michail Schizas², Edward DiCarlo¹, Susan Goodman¹, Christina Leslie³, Laura Donlin¹ and Alexander Rudensky⁴, ¹Hospital for Special Surgery, New York, NY, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Computational and Systems Biology Program Memorial Sloan Kettering Cancer Center, New York, NY, ⁴Memorial Sloan Kettering Cancer Center / Howard Hughes Medical Institute, New York, NY
Background/Purpose: Treatment-refractory rheumatoid arthritis (RA) represents a major unmet need with substantial societal burden. Targeting RA-associated fibroblast-like synoviocytes (FLS) may provide a less-immunosuppressive therapeutic option.…
Abstract Number: 0040 • ACR Convergence 2021
M1-M2 Polarization by CTLA4-Ig (Abatacept) on Cultured Circulating Monocytes from Rheumatoid Arthritis Patients and Healthy Subjects
Samuele tardito¹, Stefano Soldano², Emanuele Gotelli², Paola Montagna¹, Rosanna Campitiello², Sabrina Paolino², Carmen Pizzorni¹, Alberto Sulli², Vanessa Smith³ and Maurizio Cutolo², ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Dept. Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ³Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disorder affecting 1% of the population worldwide [1]. Monocytes/macrophages are known to play a crucial role in…
Abstract Number: 0137 • ACR Convergence 2021
Antiviral Use and Healthcare Resource Utilization Among Patients with Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016–2019
Edward Neuberger¹, Tu My To¹, Arpamas Seetasith¹, Stella Arndorfer² and Christopher Wallick¹, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research, South San Francisco, CA
Background/Purpose: Seasonal influenza poses a large burden on the healthcare system. Patients with certain chronic diseases, such as rheumatoid arthritis (RA), are especially vulnerable to…
Abstract Number: 0227 • ACR Convergence 2021
Work Participation Is Impaired Months Before Clinical Arthritis Is Apparent
Cleo Rogier¹, Pascal de Jong², Annette H.M van der Helm-van Mil³ and Elise van Mulligen⁴, ¹Erasmus MC, Rotterdam, ²Erasmus MC, Hendrik Ido Ambacht, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Work participation is still a major issue for patients with rheumatoid arthritis (RA) despite improved management and outcomes. Work loss can be divided into…
Abstract Number: 0279 • ACR Convergence 2021
Macrophage Cholesterol Loading Associates with Low-density Lipoprotein Structure, Oxidation, Antibodies Against Oxidized Epitopes and Is Modified by Immunomodulatory Treatments in Patients with Rheumatoid Arthritis
George Karpouzas¹, Bianca Papotti², sarah ormseth³, Marcella Palumbo⁴, Elizabeth Hernandez³, Cinzia Marchi⁴, Francesca Zimetti⁴, Franco Bernini⁴ and Nicoletta Ronda⁴, ¹Harbor-UCLA Medical Center, Torrance, CA, ²2. Department of Food and Drug, University of Parma, Italy, Parma, Italy, ³The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, ⁴Department of Food and Drug, University of Parma, Parma, Italy
Background/Purpose: In Rheumatoid arthritis (RA), immune dysregulation, excess inflammation and oxidative stress may alter lipoprotein level and function and promote LDL oxidation and its uptake…
Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Kathryn Starzyk¹, Gary Curhan² and Julia Brault², ¹OM1, Inc, Boston, MA, ²OM1, Boston, MA
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
Abstract Number: 0527 • ACR Convergence 2021
Role of Terminal Uridylyl Transferase 7 in TNF-α-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts In Vitro
Anil singh, farheen Shaikh and Salah-uddin Ahmed, Washington State University, Spokane, WA
Background/Purpose: Terminal uridylyl transferase 7 (TUT7), also known as Zcchc6, is a zinc finger domain-containing protein responsible for terminal uridylation of miRNA, implicated in pre-miRNA…
Abstract Number: 0581 • ACR Convergence 2021
Rheumatoid Arthritis Treatment Patterns in Massachusetts: Informative Findings from Insurance Claims Data
Mark Matza¹, D. Steven Fox², Kay Larholt³, David Fritsche³, Elizabeth Apgar³, Mitesh Puthran³, Gigi Hirsch³ and Marcy Bolster¹, ¹Massachusetts General Hospital, Boston, MA, ²University of Southern California, School of Pharmacy, Los Angeles, CA, ³Massachusetts Institute of Technology (MIT) Center for Biomedical Innovation, Cambridge, MA
Background/Purpose: A real-world current state of RA patients in Massachusetts (MA) is analyzed to provide a novel assessment of demographics, treatment patterns, and clinical settings…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].